The Final Push

Ensuring LEU Use for Medical Isotope Production



Miles A. Pomper Senior Research Associate CNS, Monterey Institute

Outline


The current situation

Recent Positive Developments

Technical, Political, and Economic Obstacles

New strategies to ensure move to LEU

Medical Isotopes: Current U.S. Mo⁹⁹ / TC^{99m} Supply Matrix



Medical isotope production: Switching from HEU to LEU or not?

Positive developments:

- Greater Political Support—UNSC 1887 and NS Summit
- U.S now receiving regular commercial shipments of medical isotopes produced using LEU fuel and targets, from South Africa and Australia
- 2016 closure of NRU
- New production capability moving forward in S Korea, S America, E Europe, US
- Conversion of Polish (2012), Czech reactors to LEU fuel

Not so positive developments:

- Delays in European licensing of Tc-99m
- Russia plans to export Mo-99 isotopes to fill in shortages in production but using HEU

Potential New Projects for Mo-99 Production

REACTOR	Six-day ci EOP/yr	Six day ci EOP/wk	Weeks/yr	Potential first year
PROJECTS WITH PROCESSING FACILITIES AS PART OF PROJECT				
ROSATOM*/**	52 000	1 000	52.0	2013
ROSATOM*/** - TOTAL	130 000	2 500	52.0	2013
Babcock and Wilcox	144 000	3 000	48.0	2014
advanced RR***	25 710	1 000	25.7	2015
CNEA, Argentina	-	-	-	2018
SAFARI - 2	108 930	2 500	43.5	2020
PROJECTS REQUIRING ADDITIONAL PROCESSING FACILITIES****				
MURR**	156 000	3 000	52.0	2012
FRM - 11**	102 860	3 000	34.3	2015
GE -	144 000	3 000	48.0	2014
US - LEU target technology	144 000	3 000	48.0	2014
US - Accelerator technology	144 000	3 000	48.0	2014
India	-	-	-	2015
OPAL	-	-	-	2015
INR, **	120 000	3 000	40.0	2015
Jules Horowitz***	108 000	3 000	36.0	2016
South Korea	-	-	-	2017
PALLAS	266 390	6 215	42.9	2020
MYRRHA	178 290	5 200	34.3	2022

* Project includes three reactors, two of which would be used to produce Mo-99 in a continuous fashion, with the third being a back up.

** Research reactor already exists, but is not yet irradiating targets for Mo-99 production.

*** Under active construction.

**** Projects in Europe would face a processing capacity limitation.

SOURCE: OECD Nuclear Energy Agency

The South African Experience

 Mo-99 producer NECSA has committed to operate solely on LEU

- \$25 million from NNSA to produce fully LEU-based isotopes
- 2009: reactor fueled only with LEU
- Current: Anticipates using only LEU targets for Mo-99 production-2013
- 2 X density of LEU targets
- More waste, problems with Mo-yield, NECSA wants to develop higherdensity targets
- Costs 10% more than HEU process but little cost impact on patients
- Tc-99m licensed quickly by FDA, but not by EU states
 - Expensive, cumbersome process of country-by country validation tests. necessary



Conversion: Not Mainly Technical Challenge

- 2009 National Academies of Science study:
 - "...no technical reasons that adequate quantities [of medical isotopes] cannot be produced from LEU targets in the future."
- Fuel at major production reactors has been converted to LEU
 - BR2 only exception, but seeking to convert

Need to develop LEU targets

 LEU substitution would require reactor and Mo-99 processors to process about five times as many targets and an equivalent increase in waste.

 Make targets larger, or with greater uranium density, or with more uranium and less cladding

Conversion: Not Mainly Technical Challenge (2)

- Production costs would likely rise marginally compared to the existing HEU targets and processes, but without significantly increasing the cost of diagnostic imaging.
- To minimize disruption, seek to ensure LEU targets are compatible with existing processes for target dissolution and Mo-99 recovery and minimize waste
 - Advantage of reactor irradiation vs. neutron capture etc (different specific activity levels)

Conversion: An Economic Problem

Instability in Mo-99 market

- Exemplified by the shut down of aging NRU Chalk River reactor 2009-2010
- No incentive for creation of new irradiation facilities due to operating subsidies
- Government reimbursements rates for isotopes do not reflect the full costs of processing and other production
- Lack of adequate geographic distribution hampers supply
- Concerns that conversion could lead to shortages

Conversion: An Economic Problem (2)

Processors resist additional \$ of conversion

- Changes to processing may be needed to accommodate higher throughput levels
- Limited access to needed addl. reactor irradiation time
- LEU isotopes need to be licensed

Russia

- Kiriyenko: LEU production the goal but need to ensure market supply
- There are some indications Russia in the short term may switch to LEU fuel, but not targets
- Better to convert now to LEU than gear up HEU production
- Are incentives needed to ensure move?
 - Letter from NNSA Administrator D'Agostino to Congress positive move—Calls for Congress to consider measures to counter subsidized HEU-based production
 - Possibilities include labeling, addl export constraints, preferential gov procurement

Recent Responses to Instability

Governments sought ways to ensure sufficient supply

- Asked the OECD Nuclear Energy Agency and the IAEA for recommendations for altering the market structure
- Better sharing of information about proposed reactor shutdowns and conversion

Reduced demand:

- Physicians and other participants chose alternatives or were conservative in using their supply of isotopes
- Increased production: New entrants or local reactors reaching the global market (all HEU)
 - Poland—converting to LEU fuel (2012)
 - Czech Republic—converted to LEU fuel
 - Russia-?

Policy Prescriptions Offered

US Congressional Action

- First introduced in 2009, passed House
- Revised version has passed Senate recently
 - Would ban US exports of HEU for targets to Western Europe and Canada
 - Authorizes efforts to promote Mo-99 production through LEU fuels and targets, including the construction of domestic facilities
 - Would establish government responsibility for waste disposition

OECD Nuclear Energy Agency

Governments should terminate subsidies

New Strategies (1)

Commitment by leaders at the 2012 NSS

- phase out deadline for HEU use for medical isotope
- USG has sought this
- May need to push date back some– 2018-2020?

Further restrictions on US HEU exports

– Informal

Subsidy cutoffs

- Governments should more quickly raise prices of irradiated Mo-99 produced using HEU fuel or targets to market levels as suggested by the HLG-MR
- US could consider countervailing duties for those who continue to use subsidized production (subsidized production will also tend to be HEU)

New Strategies

Preferential procurement

- By National governments and the WHO
- Need clear studies by US and NEA of alternative strategies of preferential procurement strategies and costs and benefits
- Should consider supporting or requiring government purchases of LEUbased isotopes
- Natl governments should agree to take steps to move quickly to license LEU-based isotopes
- Taxing HEU or ensuring full cost of HEU (enrichment)

US Market power

- World's largest importer of Mo-99
- The US could impose tariffs or a ban on the import of HEU-based isotopes
- Once sufficient LEU supplies available